DOCSLIB.ORG

Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ Published OnlineFirst March 1, 2017; DOI: 10.1158/0008-5472.CAN-16-3229 Cancer Molecular and Cellular Pathobiology Research Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ Zhen Wang1,2, Peng Liu1,2, Xin Zhou1,2, Tianxiang Wang1, Xu Feng1,2, Yi-Ping Sun1, Yue Xiong1,3, Hai-Xin Yuan1, and Kun-Liang Guan1,4 Abstract Endothelin receptor A (ETAR) promotes tumorigenesis by induced YAP/TAZ dephosphorylation, nuclear accumulation, and stimulating cell proliferation, migration, and survival. However, transcriptional activation in multiple colon cancer cells. ETAR the mechanism of ETAR in promoting tumor growth is largely stimulation acted via downstream G-protein Gaq/11 and Rho unknown. In this study, we demonstrate that ETAR stimulates GTPase to suppress the Hippo pathway, thus leading to YAP/TAZ colon cell proliferation, migration, and tumorigenesis through activation, which was required for ETAR-induced tumorigenesis. the activation of YAP/TAZ, two transcription coactivators of Overall, these results indicate a critical role of the YAP/TAZ axis in the Hippo tumor suppressor pathway. Endothelin-1 treatment ETAR signaling. Cancer Res; 77(9); 2413–23. Ó2017 AACR. Introduction tumor growth and progression, angiogenesis, and metastatic spread(4,5,8).TheimportanceofETARincancerindicates The endothelin family consists of a group of 21-amino acid that ETAR-specific antagonists (e.g., BQ123, atrasentan, and peptides produced primarily in the endothelium, epithelium, and ZD4054) are potential cancer therapeutic drugs. In fact, ETAR smooth muscle cells (1, 2). Among the three isoforms of endothe- activation induces the activity of tumor-related proteinases and lins, endothelin-1 (ET-1) is the most abundant and widely subsequently promotes cell migration and cell invasion, which expressed. Extensive studies have revealed a wide range of bio- could be blocked by BQ123 (9, 10). logical functions of ET-1, including vasoconstriction, cell prolif- Consistent with a prominent role of ET-1 in tumorigenesis, eration, and cell migration (3). In addition, ET-1 signaling has several ETAR antagonists have been tested in clinical trials. been involved in tumorigenesis in multiple tissues (4). It acts as a Atrasentan showed significant positive effects in brief pain growth factor in several cancers, including carcinoma of the inventory, PSA progression, and bone markers on patients in prostate, ovary, colon, cervix, breast, kidney, lung, central nervous phase I and II trials (11). In a phase III prostate cancer trial, system tumors as well as melanoma, Kaposi sarcoma, and bone atrasentan treatment showed improvement in the median time metastasis (5, 6). to disease progression in patients, although the primary end- ET-1 signals through plasma membrane–localized endothe- point was not achieved (12, 13). Atrasentan is also under phase lin receptor A (ETAR) and endothelin receptor B (ETBR), two II trials for other types of cancer, including renal, ovarian, non– classical G-protein–coupled receptors (GPCR). ETAR has been small cell lung, and brain cancers (11). ZD4054 (also known as reported to be a primary vasoconstrictor and growth-promoting zibotentan) is a specific ETAR antagonist and has been studied receptor, whereas ETBR inhibits cell growth and vascular con- in a multicenter phase II, randomized, double blind, placebo- striction (1, 7). Upon activation by ET-1, ETAR contributes controlled trial. Patients that received ZD4054 experienced a to cell proliferation, migration, and survival. It also promotes 35% reduction in the risk of death, which has showed improved overall survival (14). ZD4054 is being evaluated in 1Key Laboratory of Molecular Medicine of Ministry of Education and Institutes of hormone-resistant prostate cancer in phase III clinical trials Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, (15, 16). In addition, Bosentan and YM598, two nonselective 2 3 China. School of Life Sciences, Fudan University, Shanghai, China. Department antagonists for both ETAR and ETBR, have shown promising of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, therapeutic effect on prostate cancer in clinical trials (17). University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4Depart- ment of Pharmacology and Moores Cancer Center, University of California, San Previous studies have shown higher expression of ETAR and ET- Diego, La Jolla, California. 1 in colon cancer tissue compared with normal tissue (18–20), whereas ETBR is expressed in a contrary pattern (21). In addition, Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). ETAR expression correlates with liver metastases of colorectal cancers (20, 21). ETAR may also promote colon cancer cell Corresponding Authors: Kun-Liang Guan, UCSD, RM 5333, 3855 Health Sciences Drive, La Jolla, CA 92093-0815. Phone: 858-822-7945; Fax: 858- survival in response to chemotherapy, such as cisplatin (20). A fi 534-7638; E-mail: [email protected]; Yue Xiong, [email protected]; and Hai-Xin preclinical study demonstrated that ZD4054 ef ciently sup- Yuan, Key Laboratory of Molecular Medicine of Ministry of Education and pressed colorectal cancer cell growth and progression, indicating Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, its potential role as adjuvant therapy in colorectal cancer (22). Shanghai 20032, China. E-mail: [email protected] However, the molecular mechanism of ETAR in promoting tumor doi: 10.1158/0008-5472.CAN-16-3229 cell survival, growth, or metastasis in colorectal cancer is not fully Ó2017 American Association for Cancer Research. understood. www.aacrjournals.org 2413 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst March 1, 2017; DOI: 10.1158/0008-5472.CAN-16-3229 Wang et al. The Hippo pathway was initially identified to be key player in Cell culture and transfection organ size control in Drosophila and lately found to be important HCT116 cells were cultured in McCoy's 5A medium (Sigma) in human cancer (23–26). The core components of the mamma- supplemented with 10% FBS (Gibco) and 50 mg/mL penicillin/ lian Hippo pathway contain a kinase cascade of MST1/2, MAP4Ks, streptomycin. Used in our current study, HCT116, HEK293T, and and LATS1/2, in which MST1/2 or MAP4Ks phosphorylate and ZR-75-30 cells were obtained from the ATCC in 2015, where they activate LATS. This kinase cascade regulates target genes expres- were characterized by Mycoplasma detection, isozyme detection, sion by inhibiting its downstream transcriptional coactivators DNA fingerprinting, and cell vitality detection. SW480, HT29, Yes-associated protein (YAP) and transcriptional coactivator SW620, SKBR3, MDA-MB-231, MCF7, and Du145 cells were with PDZ-binding motif (TAZ). LATS1/2 restrict the activity of purchased from cell bank of Chinese Academy of Sciences (Beij- YAP/TAZ by direct phosphorylation (27). Phosphorylated YAP/ ing, China) in 2014, where these cells were characterized by TAZ are sequestered in the cytoplasm by 14-3-3 binding (28–30). Mycoplasma detection, isozyme detection, DNA fingerprinting, Inhibition of LATS1/2 activity leads to dephosphorylation of YAP/ and cell vitality detection. These cells were maintained in DMEM TAZ, which then translocate to the nucleus, bind to the TEA medium (Invitrogen) supplemented with 10% FBS (Gibco) and domain family transcription factors (TEAD1-4), and promote the 50 mg/mL penicillin/streptomycin. PC3 cells were purchased in expression of target genes (31, 32). Generally, the Hippo pathway 2015 from Cell Center of the Institutes of Biomedical Sciences acts as an important inhibitor of tissue growth and organ size by (IBS), Fudan University (Shanghai, China), where these cells were controlling cell proliferation, apoptosis, and migration in characterized by Mycoplasma detection, isozyme detection, DNA response to a variety of extracellular and intracellular signals, fingerprinting, and cell vitality detection. PC3 cells were cultured including GPCR signaling (33, 34). in F12 medium (Sigma) supplemented with 10% FBS (Gibco) ETAR activation by ET-1 has been reported to induce the and 50 mg/mL penicillin/streptomycin. All cell lines were cultured expression of connective tissue growth factor (CTGF) and cyste- at 37 C with 5% CO2 and immediately stored in liquid nitrogen ine-rich protein 61 (CYR61), two well-defined target genes of the till use. A new frozen vial of the same batch of cells was restarted Hippo pathway (35–38), indicating that ET-1 may act upstream of every 2 to 3 months. For serum starvation, cells were incubated in the Hippo–YAP pathway. In this study, we revealed a mechanism DMEM medium, McCoy's 5A medium, or F12 medium, respec- of YAP/TAZ activation by ET-1/ETAR and its role in colorectal tively. Cells were transfected with plasmid DNA using Lipofecta- tumorigenesis. min2000 reagent (Invitrogen). siRNAs were transfected into cells following the manufacturer's instructions for Lipofectamine Materials and Methods RNAiMAX reagent (Invitrogen). To generate stable YAP/TAZ knocking-down cells, pMKO- Chemicals shScramble and pMKO-shTAZ retroviruses, which were produced Chemicals that were used in this study: Endothelin-1, in HEK293T cells using VSVG and GAG as packaging plasmids, BQ123, Tetramethylrhodamine B isothiocyanate-conjugated were used to infect HCT116 cells. pLKO-shYAP lentivirus was Phalloidin, and Latrunculin B
Load more

Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • Lysophosphatidic Acid and Its Receptors: Pharmacology and Therapeutic Potential in Atherosclerosis and Vascular Disease
    JPT-107404; No of Pages 13 Pharmacology & Therapeutics xxx (2019) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease Ying Zhou a, Peter J. Little a,b, Hang T. Ta a,c, Suowen Xu d, Danielle Kamato a,b,⁎ a School of Pharmacy, University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD 4102, Australia b Department of Pharmacy, Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou 510520, China c Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, St Lucia, QLD 4072, Australia d Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA article info abstract Available online xxxx Lysophosphatidic acid (LPA) is a collective name for a set of bioactive lipid species. Via six widely distributed G protein-coupled receptors (GPCRs), LPA elicits a plethora of biological responses, contributing to inflammation, Keywords: thrombosis and atherosclerosis. There have recently been considerable advances in GPCR signaling especially Lysophosphatidic acid recognition of the extended role for GPCR transactivation of tyrosine and serine/threonine kinase growth factor G-protein coupled receptors receptors. This review covers LPA signaling pathways in the light of new information. The use of transgenic and Atherosclerosis gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have Gproteins fi β-arrestins provided many insights into the biological signi cance of LPA and individual LPA receptors in the progression Transactivation of atherosclerosis and vascular diseases.
    [Show full text]
  • How Relevant Are Bone Marrow-Derived Mast Cells (Bmmcs) As Models for Tissue Mast Cells? a Comparative Transcriptome Analysis of Bmmcs and Peritoneal Mast Cells
    cells Article How Relevant Are Bone Marrow-Derived Mast Cells (BMMCs) as Models for Tissue Mast Cells? A Comparative Transcriptome Analysis of BMMCs and Peritoneal Mast Cells 1, 2, 1 1 2,3 Srinivas Akula y , Aida Paivandy y, Zhirong Fu , Michael Thorpe , Gunnar Pejler and Lars Hellman 1,* 1 Department of Cell and Molecular Biology, Uppsala University, The Biomedical Center, Box 596, SE-751 24 Uppsala, Sweden; [email protected] (S.A.); [email protected] (Z.F.); [email protected] (M.T.) 2 Department of Medical Biochemistry and Microbiology, Uppsala University, The Biomedical Center, Box 589, SE-751 23 Uppsala, Sweden; [email protected] (A.P.); [email protected] (G.P.) 3 Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Box 7011, SE-75007 Uppsala, Sweden * Correspondence: [email protected]; Tel.: +46-(0)18-471-4532; Fax: +46-(0)18-471-4862 These authors contributed equally to this work. y Received: 29 July 2020; Accepted: 16 September 2020; Published: 17 September 2020 Abstract: Bone marrow-derived mast cells (BMMCs) are often used as a model system for studies of the role of MCs in health and disease. These cells are relatively easy to obtain from total bone marrow cells by culturing under the influence of IL-3 or stem cell factor (SCF). After 3 to 4 weeks in culture, a nearly homogenous cell population of toluidine blue-positive cells are often obtained. However, the question is how relevant equivalents these cells are to normal tissue MCs. By comparing the total transcriptome of purified peritoneal MCs with BMMCs, here we obtained a comparative view of these cells.
    [Show full text]
  • Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020)
    University of Kentucky UKnowledge Theses and Dissertations--Medical Sciences Medical Sciences 2020 Involvement of the Sigma-1 Receptor in Methamphetamine- Mediated Changes to Astrocyte Structure and Function Richik Neogi University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0002-8716-8812 Digital Object Identifier: https://doi.org/10.13023/etd.2020.363 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Neogi, Richik, "Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020). Theses and Dissertations--Medical Sciences. 12. https://uknowledge.uky.edu/medsci_etds/12 This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Association of Single Nucleotide Polymorphisms of Endothelin
    Association of Single Nucleotide Polymorphisms of Endothelin, Orexin and Vascular Endothelial Growth Factor Receptor Genes with Obstructive Sleep Apnea among Thai Ethnic Kankanit Rattanathanawan PhD*, Panaree Busarakumtragul PhD**, Polphet Thongket MSc****, Chairat Neruntarat MD***, Wasana Sukhumsirichart PhD**** * Innovative Learning Center, Srinakharinwirot University, Bangkok, Thailand ** Department of Physiology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand *** Department of Otolaryngology, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand **** Department of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand Background: Obstructive sleep apnea (OSA) is a complex disorder characterized by repetitive collapse of upper airway during sleep which strongly influenced by genetic factors, especially those affect regulation of the sleep-wake cycle and endothelial function. Objective: This study investigated the association between single nucleotide polymorphisms (SNPs) in endothelin (EDNRA), orexin (OX1R, OX2R) and vascular endothelial growth factor (VEGFR1) receptor genes with risk of OSA in Thai population. Material and Method: All subjects were diagnosed by overnight polysomnography (PSG) before divided into OSA (59) and NOSA (60) groups based on their apnea-hypopnea index (AHI). Serum lipid levels were examined by using enzymatic colorimetric and homogeneous methods. DNAs were extracted and genotyped the SNPs by polymerase chain reaction (PCR) and high-resolution
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Peripheral Regulation of Pain and Itch
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1596 Peripheral Regulation of Pain and Itch ELÍN INGIBJÖRG MAGNÚSDÓTTIR ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-513-0746-6 UPPSALA urn:nbn:se:uu:diva-392709 2019 Dissertation presented at Uppsala University to be publicly examined in A1:107a, BMC, Husargatan 3, Uppsala, Friday, 25 October 2019 at 13:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Professor emeritus George H. Caughey (University of California, San Francisco). Abstract Magnúsdóttir, E. I. 2019. Peripheral Regulation of Pain and Itch. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1596. 71 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0746-6. Pain and itch are diverse sensory modalities, transmitted by the somatosensory nervous system. Stimuli such as heat, cold, mechanical pain and itch can be transmitted by different neuronal populations, which show considerable overlap with regards to sensory activation. Moreover, the immune and nervous systems can be involved in extensive crosstalk in the periphery when reacting to these stimuli. With recent advances in genetic engineering, we now have the possibility to study the contribution of distinct neuron types, neurotransmitters and other mediators in vivo by using gene knock-out mice. The neuropeptide calcitonin gene-related peptide (CGRP) and the ion channel transient receptor potential cation channel subfamily V member 1 (TRPV1) have both been implicated in pain and itch transmission. In Paper I, the Cre- LoxP system was used to specifically remove CGRPα from the primary afferent population that expresses TRPV1.
    [Show full text]
  • Endothelins (EDN1, EDN2, EDN3) and Their Receptors (EDNRA, EDNRB, EDNRB2) in Chickens Functional Analysis and Tissue Distributi
    General and Comparative Endocrinology 283 (2019) 113231 Contents lists available at ScienceDirect General and Comparative Endocrinology journal homepage: www.elsevier.com/locate/ygcen Endothelins (EDN1, EDN2, EDN3) and their receptors (EDNRA, EDNRB, EDNRB2) in chickens: Functional analysis and tissue distribution T ⁎ Haikun Liu, Qin Luo, Jiannan Zhang, Chunheng Mo, Yajun Wang, Juan Li Key Laboratory of Bio-resources and Eco-environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, PR China ARTICLE INFO ABSTRACT Keywords: Endothelins (EDNs) and their receptors (EDNRs) are reported to be involved in the regulation of many phy- Chicken siological/pathological processes, such as cardiovascular development and functions, pulmonary hypertension, Endothelin neural crest cell proliferation, differentiation and migration, pigmentation, and plumage in chickens. However, Endothelin receptor the functionality, signaling, and tissue expression of avian EDN-EDNRs have not been fully characterized, thus Tissue expression impeding our comprehensive understanding of their roles in this model vertebrate species. Here, we reported the cDNAs of three EDN genes (EDN1, EDN2, EDN3) and examined the functionality and expression of the three EDNs and their receptors (EDNRA, EDNRB and EDNRB2) in chickens. The results showed that: 1) chicken (c-) EDN1, EDN2, and EDN3 cDNAs were predicted to encode bioactive EDN peptides of 21 amino acids, which show remarkable degree of amino acid sequence identities (91–95%) to their respective mammalian orthologs; 2) chicken (c-) EDNRA expressed in HEK293 cells could be preferentially activated by chicken EDN1 and EDN2, monitored by the three cell-based luciferase reporter assays, indicating that cEDNRA is a functional receptor common for both cEDN1 and cEDN2.
    [Show full text]
  • Morphological and Molecular Characterization of Human Dermal Lymphatic Collectors
    RESEARCH ARTICLE Morphological and Molecular Characterization of Human Dermal Lymphatic Collectors Viktoria Hasselhof1☯, Anastasia Sperling1☯, Kerstin Buttler1, Philipp StroÈ bel2, JuÈ rgen Becker1, Thiha Aung3,4, Gunther Felmerer3, JoÈ rg Wilting1* 1 Institute of Anatomy and Cell Biology, University Medical School GoÈttingen, GoÈttingen, Germany, 2 Institute of Pathology, University Medical Center GoÈttingen, GoÈttingen, Germany, 3 Division of Trauma Surgery, Plastic and Reconstructive Surgery, University Medical Center GoÈttingen, GoÈttingen, Germany, a11111 4 Center of Plastic, Hand and Reconstructive Surgery, University Medical Center Regensburg, Regensburg, Germany ☯ These authors contributed equally to this work. * [email protected] Abstract OPEN ACCESS Citation: Hasselhof V, Sperling A, Buttler K, StroÈbel Millions of patients suffer from lymphedema worldwide. Supporting the contractility of lym- P, Becker J, Aung T, et al. (2016) Morphological phatic collectors is an attractive target for pharmacological therapy of lymphedema. How- and Molecular Characterization of Human Dermal ever, lymphatics have mostly been studied in animals, while the cellular and molecular Lymphatic Collectors. PLoS ONE 11(10): e0164964. doi:10.1371/journal.pone.0164964 characteristics of human lymphatic collectors are largely unknown. We studied epifascial lymphatic collectors of the thigh, which were isolated for autologous transplantations. Our Editor: Robert W Dettman, Northwestern University, UNITED STATES immunohistological studies identify additional markers for LECs (vimentin, CCBE1). We show and confirm differences between initial and collecting lymphatics concerning the Received: July 1, 2016 markers ESAM1, D2-40 and LYVE-1. Our transmission electron microscopic studies reveal Accepted: October 4, 2016 two types of smooth muscle cells (SMCs) in the media of the collectors with dark and light Published: October 20, 2016 cytoplasm.
    [Show full text]
  • Endothelin a Receptor Blocker and Calcimimetic in the Adenine Rat
    Törmänen et al. BMC Nephrology (2017) 18:323 DOI 10.1186/s12882-017-0742-z RESEARCHARTICLE Open Access Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency Suvi Törmänen1, Ilkka Pörsti1,2,8*, Päivi Lakkisto3,4, Ilkka Tikkanen3,5, Onni Niemelä1,6, Timo Paavonen1,7, Jukka Mustonen1,2 and Arttu Eräranta1 Abstract Background: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). Methods: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n = 12), 0.3% adenine (Ade; n = 20), Ade + 50 mg/kg/day sitaxentan (n = 16), Ade + 20 mg/kg/day cinacalcet (n = 16), and Ade + sitaxentan + cinacalcet (n = 16). Blood pressure (BP) was measured using tail-cuff, kidney histology was examined, and RA components measured using RT-qPCR. Results: Adenine caused tubulointerstitial damage with severe CRI, anemia, hyperphosphatemia, 1.8-fold increase in urinary calcium excretion, and 3.5-fold and 18-fold increases in plasma creatinine and PTH, respectively. Sitaxentan alleviated tubular atrophy, while sitaxentan + cinacalcet combination reduced interstitial inflammation, tubular dilatation and atrophy in adenine-rats. Adenine diet did not influence kidney angiotensin converting enzyme (ACE) and AT4 receptor mRNA, but reduced mRNA of renin, AT1a,AT2, (pro)renin receptor and Mas to 40–60%, and suppressed ACE2 to 6% of that in controls. Sitaxentan reduced BP by 8 mmHg, creatinine, urea, and phosphate concentrations by 16–24%, and PTH by 42%. Cinacalcet did not influence BP or creatinine, but reduced PTH by 84%, and increased hemoglobin by 28% in adenine-rats.
    [Show full text]
  • Downloaded on 27 May 2020
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.07.438755; this version posted April 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Cells of the human intestinal tract mapped across space and time Elmentaite R1, Kumasaka N1, King HW2, Roberts K1, Dabrowska M1, Pritchard S1, Bolt L1, Vieira SF1, Mamanova L1, Huang N1, Goh Kai’En I3, Stephenson E3, Engelbert J3, Botting RA3, Fleming A1,4, Dann E1, Lisgo SN3, Katan M7, Leonard S1, Oliver TRW1,8, Hook CE8, Nayak K10, Perrone F10, Campos LS1, Dominguez-Conde C1, Polanski K1, Van Dongen S1, Patel M1, Morgan MD5,6, Marioni JC1,5,6, Bayraktar OA1, Meyer KB1, Zilbauer M9,10,11, Uhlig H12,13,14, Clatworthy MR1,4, Mahbubani KT15, Saeb Parsy K15, Haniffa M1,3, James KR1* & Teichmann SA1,16* Affiliations: 1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK. 2. Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London E1 2AT, UK 3. Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 4. Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK 5. European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, UK. 6. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK 7. Structural and Molecular Biology, Division of Biosciences, University College London WC1E 6BT, UK 8.
    [Show full text]
  • Novel Methylation Patterns Predict Outcome in Uveal Melanoma
    Article Novel Methylation Patterns Predict Outcome in Uveal Melanoma Sarah Tadhg Ferrier 1 and Julia Valdemarin Burnier 1,2,3,* 1 Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, H4A 3J1; [email protected] 2 Experimental Pathology Unit, Department of Pathology, McGill University; Montreal, QC, Canada, H3A 0G4 3 Department of Oncology, McGill University; Montreal, QC, Canada, H3A 0G4 * Correspondence: [email protected] Table S1. Differentially methylated genes in the Pathways in Cancer KEGG pathway with a log FC ≥ 1.5. Average Average Log Fold Change Differentially Adjusted P Beta Beta ID Gene Name Species (High vs Low Methylated Probes Value Value, Value, Risk) Low High ABL proto-oncogene 1, non- ABL1 Homo sapiens cg13440206, −1.85238 1.39E−06 0.576589 0.259088 receptor tyrosine kinase(ABL1) cg02915920 −1.84042 8.03E−06 0.482846 0.192714 cg21195763 1.685721 3.13E−19 0.573548 0.83358 ADCY2 adenylate cyclase 2(ADCY2) Homo sapiens cg14116052 2.454448 4.3E−24 0.513149 0.885217 ADCY6 adenylate cyclase 6(ADCY6) Homo sapiens cg25196508 3.480923 2.9E−25 0.188362 0.792499 AKT serine/threonine kinase AKT1 Homo sapiens cg14116052 2.454448 4.3E−24 0.513149 0.885217 1(AKT1) bone morphogenetic protein BMP4 Homo sapiens cg08046044 1.527233 3.98E−06 0.049923 0.209543 4(BMP4) cg01873886 1.789942 2.55E−05 0.026254 0.1723 Life 2020, 10, x; doi: FOR PEER REVIEW www.mdpi.com/journal/life Life 2020, 10, x FOR PEER REVIEW 2 of 22 cyclin dependent kinase inhibitor CDKN1B Homo sapiens cg06197769
    [Show full text]